Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.

Importantly, we also found that patients who received EloPd immediately after daratumumab therapy showed a trend toward better OS ( P = 0.057), lacking statistical significance after adjustment for other confounders in the multivariable model, indicating that while the timing between therapies influences PFS, it does not have as strong an impact on long-term survival.

also in 53,322 other papers

The potential influence of daratumumab exposure before EloPd salvage therapy showed borderline significance in the univariable analysis (HR 1.50, P = 0.057), but this association was not retained in the multivariable model (HR 1.21, P = 0.41).

also in 7,017 other papers

The increased risk associated with lower Hb levels dropped to a 1.4-fold rise in progression risk, nevertheless showing a P value close to significance ( P = 0.075).

also in 2,130 other papers

In contrast, for OS, the effect of low Hb, although at a different cut-off (10.6 g/l), was profound and highly significant in both the univariable and multivariable analyses.

also in 132,142 other papers

While low Hb (cut-off 9.5 g/l) was a significant predictor of poorer outcomes in the PFS univariable analysis, its significance diminished in the multivariable model, becoming only borderline significant.

also in 11,409 other papers